ak102
mAbexperimental
Clinical trial activity
8 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
7
Phase 3
3
Phase 4
0
Earliest trial started May 9, 2018 (NCT04169386)
Timeline
Indications
Mechanism of action
- Subtilisin/kexin type 9INHIBITOR
PCSK9 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05260411 | Phase 3 | Jan 26, 2022 | Akeso Pharmaceuticals, Inc. |
| NCT05255458 | Phase 3 | Nov 4, 2021 | Akeso Pharmaceuticals, Inc. |
| NCT05255094 | Phase 3 | Nov 3, 2021 | Akeso Pharmaceuticals, Inc. |
| NCT04358432 | Phase 2 | May 1, 2020 | AD Pharmaceuticals Co., Ltd. (Guangzhou), Akeso Pharmaceuticals, Inc., Fudan University |
| NCT04173793 | Phase 2 | Nov 30, 2019 | AD Pharmaceuticals Co., Ltd. (Guangzhou), Akeso Pharmaceuticals, Inc., Capital Medical University, Chinese Academy of Medical Sciences |
| NCT04173403 | Phase 2 | Nov 30, 2019 | AD Pharmaceuticals Co., Ltd. (Guangzhou), Akeso Pharmaceuticals, Inc., Chinese Academy of Medical Sciences |
| NCT03933293 | Phase 2 | Apr 30, 2019 | Akeso Pharmaceuticals, Inc., Chinese Academy of Medical Sciences |
| NCT04169386 | Phase 1 | May 9, 2018 | AD Pharmaceuticals Co., Ltd. (Guangzhou), Akeso Pharmaceuticals, Inc., Chinese Academy of Medical Sciences |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akeso Pharmaceuticals, Inc. | For profit | 8 | 8 | 3 | 2018 |
| AD Pharmaceuticals Co., Ltd. (Guangzhou) | For profit | 4 | 0 | 2 | 2018 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 4 | 0 | 2 | 2018 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2020 |
5 organizations
Page 1 / 1